Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia

JAMA

Volumn 279, Issue 9, 1998, Pages 688-695

  Yaffe, Kristine ^a,e   Sawaya, George ^b   Lieberburg, Ivan ^b,c,d   Grady, Deborah ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Athena Neurosciences Inc   (United States)

^d ELAN PHARMACEUTICALS   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; COGNITION; DEMENTIA; DRUG EFFICACY; DRUG INDICATION; ESTROGEN THERAPY; FEMALE; HORMONE ACTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0032481568     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.9.688     Document Type: Review

References (89)

1. Katzman R. Alzheimer's disease. N Engl J Med. 1986;314:964-973.
2. Evans DA. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990;68:267-289.
3. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1261-1264.
4. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993;269:2637-2641.
5. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 1994;83:979-983.
6. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc. 1994;42:919-922.
7. Kimura D. Estrogen replacement therapy may protect against intellectual decline in postmenopausal women. Horm Behav. 1995;9:312-321.
8. Paganini-Hill A, Henderson VW. The effects of hormone replacement therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J Am Geriatr Soc. 1996;44:818-822.
9. Caldwell B, Watson R. An evaluation of psychologic effects of sex hormone administration in aged women: results after six months. J Gerontol. 1952;7:228-244.
10. Rauramo L, Lagerspetz K, Engblom P, Punnonen R. The effect of castration and peroral estrogen therapy on some psychological functions. Front Horm Res. 1975;3:94-104.
11. Hackman BW, Galbraith D. Replacement therapy and piperazine oestrone sulphate ('Harmogen') and its effect on memory. Curr Med Res Opin. 1976;4:303-306.
12. Campbell S, Whitehead M. Oestrogen therapy and the menopausal syndrome. Clin Obstet Gynaecol. 1977;4:31-47.
13. Fedor-Freybergh P. The influence of oestrogens on the wellbeing and mental performance in climacteric and postmenopausal women. Acta Obstet Gynecol Scand Suppl. 1977;64:1-91.
14. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345-357.
15. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol. 1991;78:991-995.
16. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485-495.
17. Heyman A, Wilkinson WE, Stafford JA, et al. Alzheimer's disease: a study of epidemiological aspects. Ann Neurol. 1984;15:335-341.
18. Amaducci LA, Fratiglioni L, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology. 1986;36:922-931.
19. Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology. 1990;40:1698-1707.
20. Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer's disease. Ann Neurol. 1990;28:766-774.
21. Brenner DE, Kukull WA, Stergachis A, et al. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population-based case-control study. Am J Epidemiol. 1994;140:262-267.
22. Henderson VW, Paganini HA, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women: comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol. 1994;51:896-900.
23. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994;140:256-261.
24. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci. 1995;7:334-337.
25. Tang MX, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429-432.
26. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517-1521.
27. Fillit H, Weinreb H, Cholst I, et al. Observations in a preliminary open trial of estradiol therapy for senile dementia-Alzheimer's type. Psychoneuroendocrinology. 1986;11:337-345.
28. Honjo H, Ogino Y, Naitoh K, et al. In vivo effects by estrone sulfate on the central nervous systemsenile dementia (Alzheimer's type). J Steroid Biochem. 1989;34:521-525.
29. Honjo H, Ogino Y, Naitoh K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: a placebo-controlled double blind study. J Jpn Menopause Soc. 1993;1:167-171.
30. Ohkura T, Isse K, Akazawa K, et al. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr J. 1994;41:361-371.
31. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
32. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177-188.
34. Oxman AD, Cook DJ, Guyatt GH, et al, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature, VI: how to use an overview. JAMA. 1994;72:1367-1371.
35. McEwen BS, Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol. 1994-29:431-436.
36. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dy sfunction. Science. 1982;217:408-414.
37. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983;219:1184-1190.
38. Luine VN. Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats. Exp Neurol. 1985;89:484-490.
39. O'Malley CA, Hautamaki RD, Kelley M, Meyer EM. Effects of ovariectomy and estradiol benzoate on high affinity choline uptake, ACh synthesis, and release from rat cerebral cortical synaptosomes. Brain Res. 1987;403:389-392.
40. Gibbs RB, Hashash A, Johnson DA. Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats. Brain Res. 1997;749:143-146.
41. Honjo H, Tamura T, Matsumoto Y, et al. Estrogen as a growth factor to central nervous cells: estrogen treatment promotes development of acetylcholinesterase-positive basal forebrain neurons transplanted in the anterior eye chamber. J Steroid Biochem Mol Biol. 1992;41:633-635.
42. Toran-Allerand C, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A. 1992;89:4668-4672.
43. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging. 1994;15(suppl 2):S195-S197.
44. Dohanich GP, Fader AJ, Javorsky DJ. Estrogen and estrogen-progesterone treatments counteract the effect of scopolamine on reinforced T-maze alternation in female rats. Behav Neurosci. 1994;108:988-992.
45. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect. 1993;91:135-159.
46. Luine VN, Khylchevskaya RI, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res. 1975;86:293-306.
47. Poirier MF, Loo H, Dennis T, Le FG, Scatton B. Platelet monoamine oxidase activity and plasma 3,4-dihydroxyphenylethylene glycol levels during the menstrual cycle. Neuropsychobiology. 1985;14:165-169.
48. Klaiber EL, Broverman DM, Vogel W, Kobayashi Y. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry. 1979;36:550-554.
49. Aylward M. Plasma tryptophan levels and mental depression in postmenopausal subjects: effects of oral piperazine-oestrone sulphate. IRCS Med Sci. 1973;1:30-34.
50. Thomson J, Maddock J, Aylward M, Oswald I. Relationship between nocturnal plasma oestrogen concentration and free plasma tryptophan in perimenopausal women. J Endocrinol. 1977;72:395-396.
51. Summer BE, Fink G. Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat. J Steroid Biochem Mol Biol. 1995;54:15-20.
52. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216-1222.
53. Drachman DA, Leber P. Treatment of Alzheimer's disease: searching for a breakthrough, settling for less. N Engl J Med. 1997;336:1245-1247.
54. Sass KJ, Spencer DD, Kim JH, et al. Verbal memory impairment correlates with hippocampal pyramidal cell density. Neurology. 1990;40:1694-1697.
55. Matsumoto A. Synaptogenic action of sex steroids in developing and adult neuroendocrine brain. Psychoneuroendocrinology. 1991;16:25-40.
56. Gould E, Woolley CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci. 1990;10:1286-1291.
57. Paganini- Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988;97:519-522.
58. Applebaum-Bowden D, McLean P, Steinmetz A, et al. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res. 1989;30:1895-1906.
59. Gangar KF, Vyas S, Whitehead M, et al. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet. 1991;338:839-842.
60. Sullivan TJ, Karas RH, Aronovitz M, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest. 1995;96:2482-2488.
61. Behl C, Widmann M, Trapp T, Holsboer F. 17-Beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun. 1995;216:473-482.
62. Goodman Y, Bruce AJ, Cheng B, Mattson MP. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem. 1996;66:1836-1844.
63. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol. 1995;38:6-14.
64. Yaffe K, Cauley J, Sands L, Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol. 1997;54:1110-1114.
65. Honjo H, Tanaka K, Kashiwagi T, et al. Senile dementia-Alzheimer's type and estrogen. Horm Metab Res. 1995;27:204-207.
66. Srivastava RA, Bhasin N, Srivastava N. Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen. Biochem Mol Biol Int. 1996;38:91-101.
67. Jaffe AB, Toran-Allerand C, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem. 1994;269:13065-13068.
68. Green PS, Gridley KE, Simpkins JW. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett. 1996;218:165-168.
69. Kittner SJ, White LR, Farmer ME, et al. Methodological issues in screening for dementia: the problem of education adjustment. J Chronic Dis. 1986;39:163-170.
70. Aronson MK, Ooi WL, Morgenstern H, et al. Women, myocardial infarction, and dementia in the very old. Neurology. 1990;40:1102-1106.
71. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intern Med. 1991;115:455-456.
72. Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol. 1990;163:1438-1444.
73. Egeland GM, Kuller LH, Matthews KA, et al. Premenopausal determinants of menopausal estrogen use. Prev Med. 1991;20:343-349.
74. Posthuma WF, Westendorp RG, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994;308:1268-1269.
75. Cobb JL, Wolf PA, Au R, White R, D'Agostino RB. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham Study. Neurology. 1995;45:1707-1712.
76. Mortimer JA, Graves AB. Education and other socioeconomic determinants of dementia and Alzheimer's disease. Neurology. 1993;43(suppl 4):S39-S44.
77. Petitti DB. Coronary heart disease and estrogen replacement therapy: can compliance bias explain the results of observational studies? Ann Epidemiol. 1994;4:115-118.
78. Horwitz RI, Viscoli CM, Berkman L, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:542-545.
79. Pizzo PA, Robichaud KJ, Edwards BK, et al. Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. J Pediatr. 1983;102:125-133.
80. The Coronary Drug Project Research Group. Influence of treatment adherence in the coronary drug project. N Engl J Med. 1981;304:612-613.
81. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
82. Petitti DB, Sidney S, Perlman JA. Increased risk of cholecystectomy in users of supplemental estrogen. Gastroenterology. 1988;94:91-95.
83. Gutthan SP, Rodriguez LG, Castellsague J, Oliart AD. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997;314:796-800.
84. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996;348:981-983.
85. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
86. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983-987.
87. Grady D, Ernster V. Does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol. 1991;134:1396-1400.
88. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589-1593.
89. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet. 1997;350:1047-1059.